Follitropin Delta (FE 999049)

DRUG3 trials

Sponsors

Ferring Pharmaceuticals

Conditions

Infertility

Phase 3

Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1

CompletedNCT01956110

Ferring PharmaceuticalsInfertility

Start: 2013-10-31End: 2017-01-03Updated: 2022-01-13

Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2

CompletedNCT01956123

Ferring PharmaceuticalsInfertility

Start: 2014-03-26End: 2017-01-03Updated: 2023-09-06

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women

CompletedNCT04773353

Ferring PharmaceuticalsInfertility

Start: 2021-12-03End: 2023-12-12Updated: 2025-01-24

Related Papers

Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France.

2026-03-11

O-014 Cumulative live birth associated with number of oocytes in ovarian stimulation with follitropin delta: an individual patient data meta-analysis

Human Reproduction2024-07-01

P-605 Effectiveness of follitropin delta in patients with potential poor response: A post hoc analysis from the ESTHER-1 trial

Human Reproduction2024-07-01

P-680 Comparison of ovarian hyperstimulation syndrome (OHSS) rates resulting from conventional dosing versus personalized dosing of follitropin delta in ovarian stimulation, analysis of RITA, ESTHER-1 trials

Human Reproduction2024-07-01

O-013 Population pharmacokinetics of follitropin delta during ovarian stimulation

Human Reproduction2024-07-01

P-655 Live birth rate in the fresh cycle associated with number of oocytes in ovarian stimulation with individualised follitropin delta: an individual patient data meta-analysis

Human Reproduction2024-07-01

P-667 Follitropin delta for ovarian stimulation in daily practice in a Dutch IVF centre

Human Reproduction2022-06-29

Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients.

2021-09-234 citations

Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta.

2021-07-1310 citations

O-114 Improved safety and efficiency of individualised versus conventional gonadotropin dosing for ovarian stimulation in IVF/ICSI: an individual patient meta-analysis (IPD-MA)

Human Reproduction2021-07-013 citations

P–650 Body weight is the main determinant of systemic follicle stimulating hormone (FSH) concentrations during controlled ovarian stimulation with follitropin delta

Human Reproduction2021-07-013 citations

P–586 Clinical outcome in frozen cycles using cryopreserved blastocysts derived from ovarian stimulation with follitropin delta

Human Reproduction2021-07-01

Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.

2018-12-2327 citations

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.

2016-11-29182 citations